Cell Signaling Technology

Cell Signaling Technology (CST) is a privately held life science company founded in 1999 in Danvers, Massachusetts, that develops and produces antibodies and proteomic tools used extensively in basic and translational biomedical research. CST is distinguished by its in-house antibody development and validation philosophy, where every antibody in their catalog is developed, produced, and validated by CST scientists in their own labs before commercial release, ensuring exceptional lot-to-lot consistency and reducing the reproducibility problems that plague the broader antibody market. Their antibodies targeting phosphorylation-dependent signaling events — including phospho-Akt, phospho-ERK, phospho-mTOR, and hundreds of other post-translational modification sites — are trusted reference standards in signal transduction research worldwide. The PathScan Sandwich ELISA kits provide quantitative, multiplex-capable protein detection in cell lysates. CST's XP rabbit monoclonal antibody technology produces highly specific reagents suitable for immunofluorescence, immunohistochemistry, flow cytometry, western blotting, and chromatin immunoprecipitation. Their Cell Signaling Technology PhosphoSitePlus database is a freely accessible curated resource documenting post-translational modification sites, referenced in hundreds of thousands of publications. SimpleChIP Plus enzymatic chromatin immunoprecipitation kits have made ChIP-seq more accessible to labs without specialized expertise. CST's antibody-based profiling arrays allow simultaneous analysis of multiple signaling nodes from a single sample, enabling pathway-level understanding of cellular responses.